Poly Medicure Limited — Investor Meet, 06-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

Poly Medicure Limited reported strong results for Q2 FY25, with revenues growing by 23% and EBITDA margins improving to 28%. The company is experiencing substantial growth, particularly in the renal business. Exports contributed significantly to this performance, especially in Europe, which saw a 35% increase. Poly Medicure plans to expand its operations, with three new facilities set to be operational by 2026. The QIP raised INR 1,000 crores for further capital expenditure and expansion.